Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
2.370
-0.060 (-2.47%)
At close: Nov 8, 2024, 4:00 PM
2.280
-0.090 (-3.80%)
After-hours: Nov 8, 2024, 7:45 PM EST

Company Description

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases.

The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).

It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.

The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.

Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Tharimmune, Inc.
Tharimmune logo
Country United States
Founded 2017
IPO Date Jan 12, 2022
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Randy Milby

Contact Details

Address:
1200 Route 22 East, Suite 2000
Bridgewater, New Jersey 08807
United States
Phone 908 955 3140
Website tharimmune.com

Stock Details

Ticker Symbol THAR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.00
CIK Code 0001861657
ISIN Number US4327052001
Employer ID 84-2642541
SIC Code 2834

Key Executives

Name Position
Randy D. Milby MBA President, Chairman and Chief Executive Officer
Sireesh Appajosyula Pharm.D. Chief Operating Officer and Director
Thomas P. Hess CPA, MBA Chief Financial Officer

Latest SEC Filings

Date Type Title
Nov 7, 2024 10-Q Quarterly Report
Sep 30, 2024 8-K Current Report
Sep 16, 2024 8-K Current Report
Aug 9, 2024 10-Q Quarterly Report
Jul 23, 2024 424B3 Prospectus
Jul 19, 2024 EFFECT Notice of Effectiveness
Jul 17, 2024 UPLOAD Filing
Jul 15, 2024 S-3 Registration statement under Securities Act of 1933
Jun 28, 2024 D Notice of Exempt Offering of Securities
Jun 20, 2024 8-K Current Report